Newsroom

News

September 21, 2023

The latest

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

Amsterdam, The Netherlands

argenx SE today announced that Health Canada has issued a Notice of Compliance authorizing VYVGARTⓇ (efgartigimod alfa) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

argenx Stories

See where we started — and where we’re going — as we chart a new course together in immunology.

Press Releases

September 21, 2023

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

September 15, 2023

argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

August 30, 2023

argenx to Present at Upcoming Investor Conferences

July 27, 2023

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

Download assets

Get photos, fact sheets, illustrations and more.

Join the team

Dare to do more with a thriving career at Argenx.

Find your career

Follow us

Get the latest news and info via our social media channels.